Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients

We implemented a carbapenem-saving strategy in hemato-oncology patients from 2013, using an empirical combination of piperacillin-tazobactam and amikacin for high-risk hemato-oncology patients with febrile neutropenia, who remain hemodynamically unstable > 72 hours despite initial cefepime treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Jae-Hoon, Kim, Si-Ho, Kang, Cheol-In, Cho, Sun Young, Lee, Nam Yong, Chung, Doo Ryeon, Peck, Kyong Ran, Song, Jae-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327090/
https://www.ncbi.nlm.nih.gov/pubmed/30636947
http://dx.doi.org/10.3346/jkms.2019.34.e17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327090/
https://www.ncbi.nlm.nih.gov/pubmed/30636947
http://dx.doi.org/10.3346/jkms.2019.34.e17

Ejemplares similares